Dyslipidemia Therapeutics Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018 to 2028

  • Published : Feb-2019
  • Tables : 33
  • Figures : 141
  • Category : Healthcare
  • No. of Pages : 170
  • Report Code : FACT2928MR
  • Format : ppt

Consolidation of Multinationals Continues, With Nearly 60% Shares

Nature of the global dyslipidemia therapeutics market remains consolidated, with leading players accounting for approximately 60% shares. Co-promotion of dyslipidemia therapeutic drugs with local or regional players, aggressive marketing, new product launches, and high investments in research and development of novel drugs are the go-to strategies being employed by leading dyslipidemia therapeutics market players to expand their global footprint. Meanwhile, local players continue to focus on expanding their manufacturing capacity to meet the growing demand for dyslipidemia drugs in the regional market. Additionally patent expiration of a multiple dyslipidemia drugs is expected to open up new opportunities for the regional players in terms of drug discovery and development. Some of the notable highlights of the dyslipidemia therapeutics market have been listed below:

  • To capitalize on the growing demand for dyslipidemia drugs in the Chinese market, AstraZeneca entered into a strategic alliance with Luye Pharma that bestowed the company with exclusive rights to promote Lyue Pharma’s Xuezhikang Capsules - a drug that has been identified as the first-line blood management medication by the Chinese government.
  • As a part of its marketing strategy, Kowa Pharmaceuticals America, Inc. launched the “Take Cholesterol to Heart” campaign, to promote the efficacy of statins in the treatment of dyslipidemia. The company is partnering with Hollywood stars and TV actors for the campaign.
  • Sanofi, a French pharmaceutical company launched Praluent, a novel dyslipidemia therapy in Korea in collaboration with Aventis Korea. This new therapy will work towards inhibiting the binding of PCSK9 to low-density lipoprotein receptors (LDLRs).
  • In January 2019, Amgen received approval for its proprietary drug Repatha from the National Medical Products Administration (NMPA) in China. The drug will be the first PCSK9 inhibitor medication for adults in China where the prevalence of dyslipidemia has increased in the recent past, triggering the demand for dyslipidemia therapeutics in the region.
  • Recent research has linked the presence of high levels of lipoprotein (a) cholesterol (Lp[a]-C), and low levels of lipoprotein cholesterol subparticle 3 (HDL3C), identifying these as novel biomarkers to diagnose the severity of coronary artery disease (CAD) in patients. The results have the potential to drive advancements in the dyslipidemia therapeutics market.

The report on the dyslipidemia therapeutics market also provides a detailed analysis of the key players operating in the dyslipidemia therapeutics market. The dyslipidemia therapeutics market report provides a comprehensive profile of leading players functioning in the dyslipidemia therapeutics market which include Merck & Co., Pfizer, Novelion Therapeutics, Mylan, Abbott Laboratories, and Novartis AG.

For full coverage of the competitive landscape, get in touch with our experts

dyslipidemia therapeutics market forecast & y o y growth

Efficacy-driven Novel Approaches for Dyslipidemia Therapeutics

Combination therapies for dyslipidemia have gained a marked significance in the recent past, deemed as an efficient solution to offset concerns regarding varied effectiveness of statins with respect to affected patients. Complementary mechanisms in combination with statins have emerged as a novel measures to ebb low-density lipoprotein levels – a key aspect enhancing the risk of dyslipidemia. Recent approval of novel drugs such as PCSK9 antibodies by regulatory authorities such as China’s National Medical Products Administration (NMPA), and The UK’s National Institute for Health and Care Excellence (NICE), alludes a rise in prevalence of novel drugs for dyslipidemia therapeutics in the near future. Medical researchers’ efforts towards the identification of new gene therapies for treatment of Mendelian lipid disorders can further open gateways to efficient dyslipidemia therapeutics and management. Additionally, leading players in the dyslipidemia therapeutics market are taking efforts to improve the overall efficacy of their dyslipidemia therapeutic drugs and are investing heavily in research and development of novel medication to target triglycerides and other lipoproteins.

For detailed analysis on all the key market factors, request a sample

Opportunities Imminent for Players, as Use of Nutraceuticals in Dyslipidemia Therapeutics Gains Significance

Shifting consumer preference towards using nutraceuticals to combat health concerns has triggered multiple researches on effectiveness of nutraceuticals in reducing lipid levels in patients. Statin intolerance is a common occurrence in patients, and nutraceuticals provide a natural alternative to keep lipids in check. Consumption of statins has been linked with certain side effects that has significantly raised concerns regarding statins among healthcare professionals and patients alike. New-onset diabetes, muscle pain, and increased incidences of hemorrhagic stroke have been reported among patients consuming statins. Nutraceuticals such has omega-3 fatty acids, soy proteins, spirulina, lupin, berberine, red yeast rice, and garlic fibers are some of the functional foods that have cholesterol-lowering benefits. Although the degree of their effectiveness on different patients is not yet fully understood, nutraceuticals are likely to gain significance as a natural treatment with no adverse effects on patients.

Collaborative and Integrated Efforts towards Drug Development to be a Key Growth Influencer

With growth palpability in patent expiration of multiple exclusive dyslipidemia therapeutic drug, pharmaceutical companies are continuously striving towards developing new and innovative solutions. However, certain factors such as lower pricing pressures, and early access to new and innovative therapies, have exacerbated the difficulties in drug development for dyslipidemia therapeutics. This has further resulted in a significant imbalance between R&D investments and profits related to dyslipidemia therapeutics.

Pharmaceutical companies are already following strategies such as open innovation, in-and-out licensing, and active technology scouting to boost innovation in dyslipidemia therapeutics development. Additionally, agency partners that offer a multidisciplinary and integrated approach for drug development will continue to sustain growth of the dyslipidemia therapeutics market. With expertise across disciplines, the agency partners could provide a solution to streamline the process of new drug development and marketing thus simplifying the drug development process for pharmaceutical companies.

Government Initiatives Aimed at Dyslipidemia Awareness to Uphold Growth

According to a report by the World Health Organization (WHO) ischemic heart diseases were identified as the leading cause of deaths around the world, accounting for 15.2 million deaths in 2016. Dyslipidemia has been associated with significant risk of ischemic heart diseases, strokes, heart attacks, and other cardiovascular conditions. Another report from WHO stated that dyslipidemia was responsible for causing 2.6 million deaths and 29.7 million disability adjusted life years. The adverse impact of the condition has prompted governments to initiate awareness campaigns and provide a proliferating environment for the development and approval of dyslipidemia therapeutics. For instance, the American College of Cardiology and American Heart Association released updated guidelines on cholesterol in November 2018 educating the population about personalized risk assessments of higher cholesterol levels and listed a set of recommended dyslipidemia therapeutic drugs. Along the same lines, UK Health Ministry ordered the rapid uptake of the newly discovered PCSK9 inhibitors with an aim to enable the beneficial treatment to reach patients quickly. The amiable environment created by regulatory authorities around the world is expected to fuel the dyslipidemia therapeutics market growth.    

Dyslipidemia Therapeutics Market - Definition

Dyslipidemia is a condition caused due to the presence of an abnormal amount of lipids such as triglycerides, fat phospholipids, and cholesterol in the blood. The presence of these lipids increases the chances of stroke, heart attacks, atherosclerosis, and other circulatory problems. Therapies and drugs used in the treatment of dyslipidemia are termed as dyslipidemia therapeutics which includes drugs such as statins, non-statins, fibrates, inhibitors, and bile acid resins.

Dyslipidemia Therapeutics Market - About the report

The report on dyslipidemia therapeutics market offers comprehensive insights into the dyslipidemia therapeutics market. The FactMR dyslipidemia market report provides a thorough assessment of the dyslipidemia market facets such as drivers, restraints, trends, opportunities, challenges, and threats.

The dyslipidemia therapeutics market report provides an accurate forecast of the dyslipidemia therapeutics market which is meant to aid stakeholders and business professionals in streamlining their strategies to obtain maximum profitability.

Dyslipidemia Therapeutics Market – Segmentation

The dyslipidemia therapeutics market report offers a detailed analysis of the dyslipidemia market on the basis of different segments. A comprehensive analysis of each of the dyslipidemia therapeutics market segments on the basis of value, Y-o-Y growth, revenue share, and CAGR has been provided in the report.

The dyslipidemia therapeutics market has been segmented on the basis of drug class, distribution channel, type, and region.

dyslipidemia therapeutics taxonomy

Dyslipidemia Therapeutics Market – Additional Questions Answered

Apart from the aforementioned insights about the dyslipidemia therapeutics market, the report answers the following questions related to dyslipidemia therapeutics market:

  • What region will hold the largest share of the dyslipidemia therapeutics market in 2019?
  • What dyslipidemia drug type currently holds the pole position in terms of revenue?
  • What dyslipidemia drug class will register the highest sales in 2019?
  • What sales channel accounted for the most dyslipidemia therapeutic drug sales in 2018?
  • What are the lucrative opportunities on offer in the dyslipidemia therapeutics market?

Dyslipidemia Therapeutics Market – Research Methodology

The key insights propounded in the dyslipidemia therapeutics market report are a consequence of thorough research. A comprehensive two-step research process was employed to survey all the aspects pertaining to the dyslipidemia therapeutics market. The report on dyslipidemia therapeutics market is a combination of detailed primary and secondary researches performed by the analysts at Fact.MR.

Results from both the phases of research were triangulated to produce an accurate and authentic forecast of the dyslipidemia therapeutics market.

Request methodology

1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FACT.MR Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction
2.1. Market Introduction
2.2. Market Definition
2.3. Market Taxonomy

3. Market Dynamics
3.1. Growth Drivers and Impact Analysis
3.2. Industry Challenges and Impact Analysis 
3.3. Industry trends and Impact analysis
3.4. Opportunity Assessment in Dyslipidemia Therapeutics Market
3.5. Macro - Economic Factors influencing demand
3.6. PESTEL Analysis

4. Global Dyslipidemia Therapeutics Market Analysis and Forecast
4.1. Global Dyslipidemia Therapeutics Market Outlook
       4.1.1. Market Value (US$ Mn) Forecast and Analysis
       4.1.2. Price Index and Price Point Assessment, by key Products
       4.1.3. Regional Demand Assessment
                4.1.3.1. Market Value Share by Region
4.2. Global Dyslipidemia Therapeutics Market Analysis by Type
       4.2.1. Low-density Lipoproteins (LDL)
       4.2.2. Triglycerides 
4.3. Dyslipidemia Therapeutics Market Analysis by Drug Class
       4.3.1. Statins
       4.3.2. Non-Statins
                4.3.2.1. PCSK9 inhibitors
                4.3.2.2. Cholesterol absorption inhibitors
                4.3.2.3. Bile Acid resins
                4.3.2.4. Fibrate
                4.3.2.5. Others
       4.3.3. Combinations Drugs
4.4. Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       4.4.1. Hospitals Pharmacies
       4.4.2. Drug Stores
       4.4.3. Retail Stores
       4.4.4. Mail Order Pharmacies 

5. North America Dyslipidemia Therapeutics Market Analysis
5.1. Introduction
       5.1.1. North America Business Outlook 
       5.1.2. North America Dyslipidemia Therapeutics Market Outlook
5.2. North America Dyslipidemia Therapeutics Market Outlook
       5.2.1. Market Value (US$ Mn) Forecast and Analysis
       5.2.2. Country Wise Demand Assessment
                5.2.2.1. US Market Value Share
                5.2.2.2. Canada Market Value Share
5.3. North America Dyslipidemia Therapeutics Market Analysis by Product Type
       5.3.1. Value (US$ Mn) Forecast by Type
       5.3.2. Y-o-Y Growth Comparison by Type 
5.4. North America Dyslipidemia Therapeutics Market Analysis by Drug Class
       5.4.1. Value (US$ Mn) Forecast by Drug Class
       5.4.2. Y-o-Y Growth Comparison by Drug Class 
5.5. North America Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       5.5.1. Value (US$ Mn) Forecast by Distribution Channel
       5.5.2. Y-o-Y Growth Comparison by Distribution Channel
5.6. Market Attractiveness Analysis

6. Latin America Dyslipidemia Therapeutics Market Analysis 
6.1. Introduction
       6.1.1. Latin America Business Outlook 
       6.1.2. Latin America Dyslipidemia Therapeutics Market Outlook
6.2. Latin America Dyslipidemia Therapeutics Market Outlook
       6.2.1. Value (US$ Mn) Forecast and Analysis
       6.2.2. Country Wise Demand Assessment
                6.2.2.1. Brazil Market Value Share
                6.2.2.2. Mexico Market Value Share 
                6.2.2.3. Rest of LA Market Value Share 
6.3. Latin America Dyslipidemia Therapeutics Market Analysis by Type
       6.3.1. Value (US$ Mn) Forecast by Type
       6.3.2. Y-o-Y Growth Comparison by Type
6.4. Latin America Dyslipidemia Therapeutics Market Analysis by Drug Class 
       6.4.1. Value (US$ Mn) Forecast by Drug Class 
       6.4.2. Y-o-Y Growth Comparison by Drug Class 
6.5. Latin America Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       6.5.1. Value (US$ Mn) Forecast by Distribution Channel
       6.5.2. Y-o-Y Growth Comparison by Distribution Channel
6.6. Market Attractiveness Analysis

7. Europe Dyslipidemia Therapeutics Market Analysis
7.1. Introduction
       7.1.1. Europe Business Outlook 
       7.1.2. Europe Dyslipidemia Therapeutics Market Outlook
7.2. Europe Dyslipidemia Therapeutics Market Outlook
       7.2.1. Value (US$ Mn) Forecast and Analysis
       7.2.2. Country Wise Demand Assessment
                7.2.2.1. Germany Market Value Share
                7.2.2.2. UK Market Value Share 
                7.2.2.3. France Market Value Share
                7.2.2.4. Spain Market Value Share 
                7.2.2.5. Italy Market Value Share
                7.2.2.6. Rest of Europe Market Value Share 
7.3. Europe Dyslipidemia Therapeutics Market Analysis by Type
       7.3.1. Value (US$ Mn) Forecast by Type
       7.3.2. Y-o-Y Growth Comparison by Type
7.4. Europe Dyslipidemia Therapeutics Market Analysis by Drug Class 
       7.4.1. Value (US$ Mn) Forecast by Drug Class 
       7.4.2. Y-o-Y Growth Comparison by Drug Class 
7.5. Europe Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       7.5.1. Value (US$ Mn) Forecast by Distribution Channel
       7.5.2. Y-o-Y Growth Comparison by Distribution Channel
7.6. Market Attractiveness Analysis

8. CIS & Russia Dyslipidemia Therapeutics Market Analysis
8.1. Introduction
       8.1.1. CIS & Russia. Business Outlook 
       8.1.2. CIS & Russia Dyslipidemia Therapeutics Market Outlook
8.2. CIS & Russia Dyslipidemia Therapeutics Market Outlook
       8.2.1. Market Value (US$ Mn) Forecast and Analysis
8.3. CIS & Russia Dyslipidemia Therapeutics Market Analysis by Type
       8.3.1. Value (US$ Mn) Forecast by Type
       8.3.2. Y-o-Y Growth Comparison by Type 
8.4. CIS & Russia Dyslipidemia Therapeutics Market Analysis by Drug Class 
       8.4.1. Value (US$ Mn) Forecast by Drug Class 
       8.4.2. Y-o-Y Growth Comparison by Drug Class 
8.5. CIS & Russia Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       8.5.1. Value (US$ Mn) Forecast by Distribution Channel
       8.5.2. Y-o-Y Growth Comparison by Distribution Channel
8.6. Market Attractiveness Analysis

9. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Analysis
9.1. Introduction
       9.1.1. Asia Pacific Excluding Japan & China Business Outlook 
       9.1.2. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Outlook
9.2. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Outlook
       9.2.1. Value (US$ Mn), Forecast and Analysis
       9.2.2. Country Wise Demand Assessment
                9.2.2.1. India Market Value Share 
                9.2.2.2. Australia & New Zealand Market Value Share
                9.2.2.3. Rest of APEJC Market Value Share 
9.3. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Analysis by Type
       9.3.1. Value (US$ Mn) Forecast by Type
       9.3.2. Y-o-Y Growth Comparison by Type 
9.4. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Analysis by Drug Class 
       9.4.1. Value (US$ Mn) Forecast by Drug Class 
       9.4.2. Y-o-Y Growth Comparison by Drug Class 
9.5. Asia Pacific Excluding Japan & China Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       9.5.1. Value (US$ Mn) Forecast by Distribution Channel
       9.5.2. Y-o-Y Growth Comparison by Distribution Channel
9.6. Market Attractiveness Analysis

10. China Dyslipidemia Therapeutics Market Analysis
10.1. Introduction
       10.1.1. China Business Outlook 
       10.1.2. China Dyslipidemia Therapeutics Market Outlook
10.2. China Dyslipidemia Therapeutics Market Outlook
       10.2.1. Market Value (US$ Mn) Forecast and Analysis
10.3. China Dyslipidemia Therapeutics Market Analysis by Type
       10.3.1. Value (US$ Mn) Forecast by Type
       10.3.2. Y-o-Y Growth Comparison by Type 
10.4. China Dyslipidemia Therapeutics Market Analysis by Drug Class 
       10.4.1. Value (US$ Mn) Forecast by Drug Class 
       10.4.2. Y-o-Y Growth Comparison by Drug Class 
10.5. China Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       10.5.1. Value (US$ Mn) Forecast by Distribution Channel
       10.5.2. Y-o-Y Growth Comparison by Distribution Channel
10.6. Market Attractiveness Analysis

11. Japan Dyslipidemia Therapeutics Market Analysis
11.1. Introduction
       11.1.1. Japan Business Outlook 
       11.1.2. Japan Dyslipidemia Therapeutics Market Outlook
11.2. Japan Dyslipidemia Therapeutics Market Outlook
       11.2.1. Market Value (US$ Mn) Forecast and Analysis
11.3. Japan Dyslipidemia Therapeutics Market Analysis by Type
       11.3.1. Value (US$ Mn) Forecast by Type
       11.3.2. Y-o-Y Growth Comparison by Type 
11.4. Japan Dyslipidemia Therapeutics Market Analysis by Drug Class 
       11.4.1. Value (US$ Mn) Forecast by Drug Class 
       11.4.2. Y-o-Y Growth Comparison by Drug Class 
11.5. Japan Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       11.5.1. Value (US$ Mn) Forecast by Distribution Channel
       11.5.2. Y-o-Y Growth Comparison by Distribution Channel
11.6. Market Attractiveness Analysis

12. MEA Dyslipidemia Therapeutics Market Analysis
12.1. Introduction
       12.1.1. MEA Business Outlook 
       12.1.2. MEA Dyslipidemia Therapeutics Market Outlook
12.2. MEA Dyslipidemia Therapeutics Market Outlook
       12.2.1. Value (US$ Mn) Forecast and Analysis
       12.2.2. Country Wise Demand Assessment
                12.2.2.1. GCC Countries Market Value Share
                12.2.2.2. South Africa Market Value Share
                12.2.2.3. Rest of MEA Market Value Share 
12.3. MEA Dyslipidemia Therapeutics Market Analysis by Type
       12.3.1. Value (US$ Mn) Forecast by Type
       12.3.2. Y-o-Y Growth Comparison by Type
12.4. MEA Dyslipidemia Therapeutics Market Analysis by Drug Class
       12.4.1. Value (US$ Mn) Forecast by Drug Class 
       12.4.2. Y-o-Y Growth Comparison by Drug Class 
12.5. MEA Dyslipidemia Therapeutics Market Analysis by Distribution Channel
       12.5.1. Value (US$ Mn) Forecast by Distribution Channel
       12.5.2. Y-o-Y Growth Comparison by Distribution Channel
12.6. Market Attractiveness Analysis

13. Competitive Assessment
13.1. Dyslipidemia Therapeutics Market Competition - a Dashboard View
13.2. Dyslipidemia Therapeutics Market Structure, By Tier

14. Company Profiles
14.1. AstraZeneca 
       14.1.1. Company Overview
       14.1.2. Key Developments
       14.1.3. Segment Financials
       14.1.4. Product Portfolio
       14.1.5. Key Strategies
14.2. Kowa Pharmaceuticals America, Inc. 
       14.2.1. Company Overview
       14.2.2. Key Developments
       14.2.3. Segment Financials
       14.2.4. Product Portfolio
       14.2.5. Key Strategies
14.3. Merck & Co. 
       14.3.1. Company Overview
       14.3.2. Key Developments
       14.3.3. Segment Financials
       14.3.4. Product Portfolio
       14.3.5. Key Strategies
14.4. Pfizer
       14.4.1. Company Overview
       14.4.2. Company Overview
       14.4.3. Key Developments
       14.4.4. Segment Financials
       14.4.5. Product Portfolio
       14.4.6. Key Strategies
14.5. Sanofi
       14.5.1. Company Overview
       14.5.2. Key Developments
       14.5.3. Segment Financials
       14.5.4. Product Portfolio
       14.5.5. Key Strategies
14.6. Amgen
       14.6.1. Company Overview
       14.6.2. Key Developments
       14.6.3. Segment Financials
       14.6.4. Product Portfolio
       14.6.5. Key Strategies
14.7. Novelion Therapeutics 
       14.7.1. Company Overview
       14.7.2. Key Developments
       14.7.3. Segment Financials
       14.7.4. Product Portfolio
       14.7.5. Key Strategies
14.8. Mylan
       14.8.1. Company Overview
       14.8.2. Key Developments
       14.8.3. Segment Financials
       14.8.4. Product Portfolio
       14.8.5. Key Strategies
14.9. Abbott Laboratories
       14.9.1. Company Overview
       14.9.2. Key Developments
       14.9.3. Segment Financials
       14.9.4. Product Portfolio
       14.9.5. Key Strategies
14.10. Novartis AG
       14.10.1. Company Overview
       14.10.2. Key Developments
       14.10.3. Segment Financials
       14.10.4. Product Portfolio
       14.10.5. Key Strategies

15. Assumptions and Acronyms Used

16. Research Methodology

Table 1: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Region
Table 2: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Type
Table 3: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
Table 4: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
Table 5: North America Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country
Table 6: North America Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Type
Table 7: North America Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
Table 8: North America Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
Table 9: Latin America Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country
Table 10: Latin America Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Type
Table 11: Latin America Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
Table 12: Latin America Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
Table 13: Europe Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country
Table 14: Europe Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Type
Table 15: Europe Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
Table 16: Europe Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
Table 17: CIS & Russia Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Type
Table 18: CIS & Russia Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
Table 19: CIS & Russia Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
Table 20: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country
Table 21: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Type
Table 22: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
Table 23: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
Table 24: Japan Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Type
Table 25: Japan Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
Table 26: Japan Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
Table 27: China Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Type
Table 28: China Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
Table 29: China Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
Table 30: MEA Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country
Table 31: MEA Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Type
Table 32: MEA Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
Table 33: MEA Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

Figure 1: Global Dyslipidemia Therapeutics Market Value Share 2018E, By Region
Figure 2: Global Dyslipidemia Therapeutics Market Value Share, By Type
Figure 3: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017
Figure 4: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 5: Global Dyslipidemia Therapeutics Market Attractiveness Analysis, By Region
Figure 6: Global Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Region
Figure 7: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017, By Low-density Lipoproteins (LDL)
Figure 8: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Low-density Lipoproteins (LDL)
Figure 9: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017, By Triglycerides
Figure 10: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Triglycerides
Figure 11: Global Dyslipidemia Therapeutics Market Attractiveness Analysis, By Type
Figure 12: Global Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Type
Figure 13: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017, By Statins
Figure 14: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Statins
Figure 15: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017, By Non-Statins
Figure 16: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Non-Statins
Figure 17: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017, By Combinations Drugs
Figure 18: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Combinations Drugs
Figure 19: Global Dyslipidemia Therapeutics Market Attractiveness Analysis, By Drug Class
Figure 20: Global Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Drug Class
Figure 21: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017, By Hospitals Pharmacies 
Figure 22: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Hospitals Pharmacies
Figure 23: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017, By Drug Stores
Figure 24: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Drug Stores
Figure 25: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017, By Retail Stores
Figure 26: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Retail Stores
Figure 27: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017, By Mail Order Pharmacies
Figure 28: Global Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028, By Mail Order Pharmacies
Figure 29: Global Dyslipidemia Therapeutics Market Attractiveness Analysis, By Distribution Channel
Figure 30: Global Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Distribution Channel
Figure 31: North America Dyslipidemia Therapeutics Market, Snapshot
Figure 32: North America Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017
Figure 33: North America Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 34: North America Dyslipidemia Therapeutics Market Value Share, by Country Type (2017A)
Figure 35: North America Dyslipidemia Therapeutics Market Value Share, by Type (2017A)
Figure 36: North America Dyslipidemia Therapeutics Market Value Share, by Drug Class (2017A)
Figure 37: North America Dyslipidemia Therapeutics Market Value Share, by Distribution Channel (2017A)
Figure 38: North America Dyslipidemia Therapeutics Market Attractiveness Analysis, By Country
Figure 39: North America Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Country
Figure 40: North America Dyslipidemia Therapeutics Market Attractiveness Analysis, By Type
Figure 41: North America Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Type
Figure 42: North America Dyslipidemia Therapeutics Market Attractiveness Analysis, By Drug Class
Figure 43: North America Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Drug Class
Figure 44: North America Dyslipidemia Therapeutics Market Attractiveness Analysis, By Distribution Channel
Figure 45: North America Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Distribution Channel
Figure 46: Latin America Dyslipidemia Therapeutics Market, Snapshot
Figure 47: Latin America Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017
Figure 48: Latin America Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 49: Latin America Dyslipidemia Therapeutics Market Value Share, by Country Type (2017A)
Figure 50: Latin America Dyslipidemia Therapeutics Market Value Share, by Type (2017A)
Figure 51: Latin America Dyslipidemia Therapeutics Market Value Share, by Drug Class (2017A)
Figure 52: Latin America Dyslipidemia Therapeutics Market Value Share, by Distribution Channel (2017A)
Figure 53: Latin America Dyslipidemia Therapeutics Market Attractiveness Analysis, By Country
Figure 54: Latin America Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Country
Figure 55: Latin America Dyslipidemia Therapeutics Market Attractiveness Analysis, By Type
Figure 56: Latin America Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Type
Figure 57: Latin America Dyslipidemia Therapeutics Market Attractiveness Analysis, By Drug Class
Figure 58: Latin America Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Drug Class
Figure 59: Latin America Dyslipidemia Therapeutics Market Attractiveness Analysis, By Distribution Channel
Figure 60: Latin America Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Distribution Channel
Figure 61: Europe Dyslipidemia Therapeutics Market, Snapshot
Figure 62: Europe Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017
Figure 63: Europe Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 64: Europe Dyslipidemia Therapeutics Market Value Share, by Country Type (2017A)
Figure 65: Europe Dyslipidemia Therapeutics Market Value Share, by Type (2017A)
Figure 66: Europe Dyslipidemia Therapeutics Market Value Share, by Drug Class (2017A)
Figure 67: Europe Dyslipidemia Therapeutics Market Value Share, by Distribution Channel (2017A)
Figure 68: Europe Dyslipidemia Therapeutics Market Attractiveness Analysis, By Country
Figure 69: Europe Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Country
Figure 70: Europe Dyslipidemia Therapeutics Market Attractiveness Analysis, By Type
Figure 71: Europe Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Type
Figure 72: Europe Dyslipidemia Therapeutics Market Attractiveness Analysis, By Drug Class
Figure 73: Europe Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Drug Class
Figure 74: Europe Dyslipidemia Therapeutics Market Attractiveness Analysis, By Distribution Channel
Figure 75: Europe Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Distribution Channel
Figure 76: CIS & Russia Dyslipidemia Therapeutics Market, Snapshot
Figure 77: CIS & Russia Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017
Figure 78: CIS & Russia Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 79: CIS & Russia Dyslipidemia Therapeutics Market Value Share, by Type (2017A)
Figure 80: CIS & Russia Dyslipidemia Therapeutics Market Value Share, by Drug Class (2017A)
Figure 81: CIS & Russia Dyslipidemia Therapeutics Market Value Share, by Distribution Channel (2017A)
Figure 82: CIS & Russia Dyslipidemia Therapeutics Market Attractiveness Analysis, By Type
Figure 83: CIS & Russia Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Type
Figure 84: CIS & Russia Dyslipidemia Therapeutics Market Attractiveness Analysis, By Drug Class
Figure 85: CIS & Russia Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Drug Class
Figure 86: CIS & Russia Dyslipidemia Therapeutics Market Attractiveness Analysis, By Distribution Channel
Figure 87: CIS & Russia Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Distribution Channel
Figure 88: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market, Snapshot
Figure 89: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017
Figure 90: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 91: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Value Share, by Country Type (2017A)
Figure 92: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Value Share, by Type (2017A)
Figure 93: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Value Share, by Drug Class (2017A)
Figure 94: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Value Share, by Distribution Channel (2017A)
Figure 95: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Attractiveness Analysis, By Country
Figure 96: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Country
Figure 97: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Attractiveness Analysis, By Type
Figure 98: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Type
Figure 99: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Attractiveness Analysis, By Drug Class
Figure 100: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Drug Class
Figure 101: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Attractiveness Analysis, By Distribution Channel
Figure 102: Asia-Pacific ex. Japan & China Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Distribution Channel
Figure 103: Japan Dyslipidemia Therapeutics Market, Snapshot
Figure 104: Japan Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017
Figure 105: Japan Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 106: Japan Dyslipidemia Therapeutics Market Value Share, by Type (2017A)
Figure 107: Japan Dyslipidemia Therapeutics Market Value Share, by Drug Class (2017A)
Figure 108: Japan Dyslipidemia Therapeutics Market Value Share, by Distribution Channel (2017A)
Figure 109: Japan Dyslipidemia Therapeutics Market Attractiveness Analysis, By Type
Figure 110: Japan Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Type
Figure 111: Japan Dyslipidemia Therapeutics Market Attractiveness Analysis, By Drug Class
Figure 112: Japan Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Drug Class
Figure 113: Japan Dyslipidemia Therapeutics Market Attractiveness Analysis, By Distribution Channel
Figure 114: Japan Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Distribution Channel
Figure 115: China Dyslipidemia Therapeutics Market, Snapshot
Figure 116: China Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017
Figure 117: China Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 118: China Dyslipidemia Therapeutics Market Value Share, by Type (2017A)
Figure 119: China Dyslipidemia Therapeutics Market Value Share, by Drug Class (2017A)
Figure 120: China Dyslipidemia Therapeutics Market Value Share, by Distribution Channel (2017A)
Figure 121: China Dyslipidemia Therapeutics Market Attractiveness Analysis, By Type
Figure 122: China Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Type
Figure 123: China Dyslipidemia Therapeutics Market Attractiveness Analysis, By Drug Class
Figure 124: China Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Drug Class
Figure 125: China Dyslipidemia Therapeutics Market Attractiveness Analysis, By Distribution Channel
Figure 126: China Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Distribution Channel
Figure 127: MEA Dyslipidemia Therapeutics Market, Snapshot
Figure 128: MEA Dyslipidemia Therapeutics Market Size (US$ Mn) Analysis, 2013–2017
Figure 129: MEA Dyslipidemia Therapeutics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028
Figure 130: MEA Dyslipidemia Therapeutics Market Value Share, by Country Type (2017A)
Figure 131: MEA Dyslipidemia Therapeutics Market Value Share, by Type (2017A)
Figure 132: MEA Dyslipidemia Therapeutics Market Value Share, by Drug Class (2017A)
Figure 133: MEA Dyslipidemia Therapeutics Market Value Share, by Distribution Channel (2017A)
Figure 134: MEA Dyslipidemia Therapeutics Market Attractiveness Analysis, By Country
Figure 135: MEA Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Country
Figure 136: MEA Dyslipidemia Therapeutics Market Attractiveness Analysis, By Type
Figure 137: MEA Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Type
Figure 138: MEA Dyslipidemia Therapeutics Market Attractiveness Analysis, By Drug Class
Figure 139: MEA Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Drug Class
Figure 140: MEA Dyslipidemia Therapeutics Market Attractiveness Analysis, By Distribution Channel
Figure 141: MEA Dyslipidemia Therapeutics Market Value Share Analysis, By Region, 2017 & 2028, By Distribution Channel

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Benefits of Becoming a Fact.MR Client

  • Access to our global market coverage
  • Periodic updates on your sector
  • Exclusive discounts and offers
  • Greater flexibility for customization
  • Quick-research assistance for ad-hoc needs
  • Access to credible insights Fact.MR analyst interactions
  • Access to Fact.MR tools and research to fuel strategy development